The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has fixed the retail prices of 11 new drug formulations, vide Order PN/272/140/2025/F/F. No. 8(140)/2025/D.P./NPPA-Div.-II dated November 28, 2025, ensuring wider access to affordable medicines for patients across the country. The notification has been issued under the provisions of the Drugs (Prices Control) Order, 2013 (DPCO-2013).
The ceiling retail prices, exclusive of GST, have been determined for formulations manufactured and marketed by respective pharmaceutical companies. These include medicines commonly prescribed for cardiac diseases, diabetes, hypertension, allergy, and severe bacterial infections.
These prices apply specifically to the manufacturers and marketers who sought price fixation through Form-I under DPCO-2013.
Compliance Requirements
The notification mandates the following:
- Manufacturers must issue updated price lists in Form-V to NPPA via IPDMS and share copies with State Drug Controllers and dealers.
- Retailers and dealers must display the updated price list prominently on their premises.
- Only actual GST paid/payable may be added over the notified price.
- In case of non-compliance or overcharging, companies will be liable to deposit the overcharged amount with interest, under DPCO-2013 and the Essential Commodities Act, 1955.
Further, previous price orders for the same strength and formulation (where applicable) stand superseded by this notification.
Government Commitment
The retail price fixation is in line with the Government of India’s ongoing efforts to:
- Improve affordability of essential and chronic-care medicines,
- Strengthen drug price regulation for patient benefit,
- Ensure accessibility of quality health care across India.
The Order can be accessed at: https://a2ztaxcorp.net/wp-content/uploads/2025/11/Notification-for-retail-price-fixation-of-new-drugs-for-11-applications.pdf
